Cipher Pharmaceuticals (TSE:CPH – Free Report) (NASDAQ:CPHR) had its target price increased by Stifel Nicolaus from C$16.00 to C$17.00 in a research report sent to investors on Wednesday, BayStreet.CA reports. They currently have a buy rating on the stock.
A number of other equities analysts have also issued reports on the company. Leede Financial lowered Cipher Pharmaceuticals from a strong-buy rating to a hold rating in a research note on Friday, September 13th. Stifel Canada raised Cipher Pharmaceuticals from a hold rating to a strong-buy rating in a report on Monday, August 12th.
Read Our Latest Report on Cipher Pharmaceuticals
Cipher Pharmaceuticals Price Performance
Cipher Pharmaceuticals (TSE:CPH – Get Free Report) (NASDAQ:CPHR) last released its quarterly earnings results on Thursday, August 8th. The company reported C$0.16 EPS for the quarter, topping analysts’ consensus estimates of C$0.15 by C$0.01. The company had revenue of C$7.26 million for the quarter, compared to the consensus estimate of C$7.52 million. Cipher Pharmaceuticals had a net margin of 102.01% and a return on equity of 28.43%. Equities analysts anticipate that Cipher Pharmaceuticals will post 1.4156977 EPS for the current year.
Cipher Pharmaceuticals Company Profile
Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.
Further Reading
- Five stocks we like better than Cipher Pharmaceuticals
- Earnings Per Share Calculator: How to Calculate EPS
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- Breakout Stocks: What They Are and How to Identify Them
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- What is the Nikkei 225 index?
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.